Thalomid
Drug
Celgene Corporation
Total Payments
$2.9M
Transactions
27
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,427 | 2 | 0 |
| 2021 | $90,293 | 2 | 0 |
| 2020 | $220,142 | 6 | 0 |
| 2019 | $72,236 | 2 | 0 |
| 2018 | $588,682 | 6 | 0 |
| 2017 | $1.9M | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $2.8M | 22 | 99.9% |
| Unspecified | $2,145 | 5 | 0.1% |
Payments by Type
General
$2.8M
22 transactions
Research
$2,145
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CG0724 - Phase II study of Rituximab in Combination with methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, vincristne, Ifosfamide, etoposide, cytarabine and Mesna (MACLO-IVAM) in Patients with Previousl | Celgene Corporation | $635.04 | 0 |
| CG0724 | Celgene Corporation | $582.40 | 0 |
| Phase II study of Rituximab in Combination with methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, vincristne, Ifosfamide, etoposide, cytarabine and Mesna (MACLO-IVAM) in Patients with Previously Untreated Mantle Cell Lymphoma (CG0724) | Celgene Corporation | $541.52 | 0 |
| A PHASE II STUDY OF THALIDOMIDE (THALOMID®), CLARITHROMYCIN (BIAXIN®), LENALIDOMIDE (REVLIMID®), AND DEXAMETHASONE (DECADRON®) FOR SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Celgene Corporation | $222.60 | 0 |
| Phase II study of Rituximab in Combination with methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, vincristne, Ifosfamide, etoposide, cytarabine and Mesna (MACLO-IVAM) in Patients with Previously Untreated Mantle Cell Lymphoma | Celgene Corporation | $163.80 | 0 |
Top Doctors Receiving Payments for Thalomid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.9M | 27 |
Ad
Manufacturing Companies
- Celgene Corporation $2.9M
Product Information
- Type Drug
- Total Payments $2.9M
- Total Doctors 0
- Transactions 27
About Thalomid
Thalomid is a drug associated with $2.9M in payments to 0 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2024. In 2024, $1,427 was paid across 2 transactions to 0 doctors.
The most common payment nature for Thalomid is "Royalty or License" ($2.8M, 99.9% of total).
Thalomid is associated with 5 research studies, including "CG0724 - Phase II study of Rituximab in Combination with methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, vincristne, Ifosfamide, etoposide, cytarabine and Mesna (MACLO-IVAM) in Patients with Previousl" ($635.04).